Financial Contrast: Zai Lab (ZLAB) and The Competition

Zai Lab (NASDAQ: ZLAB) is one of 490 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Zai Lab to related companies based on the strength of its earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Zai Lab and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Zai Lab N/A N/A N/A
Zai Lab Competitors -2,958.24% -160.23% -30.70%

Valuation & Earnings

This table compares Zai Lab and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Zai Lab N/A -$50.38 million -8.85
Zai Lab Competitors $2.01 billion $136.35 million -3.58

Zai Lab’s competitors have higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

21.2% of Zai Lab shares are held by institutional investors. Comparatively, 48.3% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 15.1% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Zai Lab and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zai Lab 0 0 3 0 3.00
Zai Lab Competitors 2981 9035 21959 619 2.58

Zai Lab presently has a consensus target price of $37.00, suggesting a potential upside of 80.22%. As a group, “Pharmaceutical preparations” companies have a potential upside of 40.78%. Given Zai Lab’s stronger consensus rating and higher probable upside, analysts clearly believe Zai Lab is more favorable than its competitors.

Zai Lab Company Profile

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics for oncology, and autoimmune and infectious disease therapies in China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor for the treatment of ovarian, breast, and lung cancers; ZL-2401, an antibiotic for the treatment of acute bacterial skin/skin structure infections, community-acquired bacterial pneumonias, and urinary tract infections; ZL-2301 that is Phase II clinical trial for the treatment of hepatocellular carcinoma; ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; ZL-2302 for the treatment of non-small cell lung cancer; and ZL-1101, an anti-OX40 antagonistic antibody for the treatment of graft-versus-host disease or systemic lupus erythematosus. The company was founded in 2013 and is headquartered in Shanghai, China.

Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply